Report cover image

Global Haemophilus Influenzae Type B Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 185 Pages
SKU # APRC20553204

Description

Summary

According to APO Research, The global Haemophilus Influenzae Type B Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Haemophilus Influenzae Type B Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Haemophilus Influenzae Type B Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Haemophilus Influenzae Type B Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Haemophilus Influenzae Type B Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Haemophilus Influenzae Type B Vaccine include Takeda Pharmaceuticals Company, Sanofi, Novartis, Merck, Lanzhou Institute of Biologica, GlaxoSmithKline, Walvax Biotechnology and Immunize BC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Haemophilus Influenzae Type B Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Haemophilus Influenzae Type B Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Haemophilus Influenzae Type B Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Haemophilus Influenzae Type B Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Haemophilus Influenzae Type B Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Haemophilus Influenzae Type B Vaccine sales, projected growth trends, production technology, application and end-user industry.

Haemophilus Influenzae Type B Vaccine Segment by Company

Takeda Pharmaceuticals Company
Sanofi
Novartis
Merck
Lanzhou Institute of Biologica
GlaxoSmithKline
Walvax Biotechnology
Immunize BC
Haemophilus Influenzae Type B Vaccine Segment by Type

Liquid Combination HIB
Liquid Monovalent HIB
Lyophilized Combination HIB
Lyophilized Monovalent HIB
Haemophilus Influenzae Type B Vaccine Segment by Application

Pharmaceutical and Biotechnology Companies
Hospital
Research Institutions
Academic Institutions
Other
Haemophilus Influenzae Type B Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilus Influenzae Type B Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Haemophilus Influenzae Type B Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilus Influenzae Type B Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Haemophilus Influenzae Type B Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Haemophilus Influenzae Type B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Haemophilus Influenzae Type B Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Haemophilus Influenzae Type B Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

185 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Haemophilus Influenzae Type B Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global Haemophilus Influenzae Type B Vaccine Market Size Estimates and Forecasts (2020-2031)
1.4 Global Haemophilus Influenzae Type B Vaccine Sales Estimates and Forecasts (2020-2031)
1.5 Global Haemophilus Influenzae Type B Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Haemophilus Influenzae Type B Vaccine Market Dynamics
2.1 Haemophilus Influenzae Type B Vaccine Industry Trends
2.2 Haemophilus Influenzae Type B Vaccine Industry Drivers
2.3 Haemophilus Influenzae Type B Vaccine Industry Opportunities and Challenges
2.4 Haemophilus Influenzae Type B Vaccine Industry Restraints
3 Haemophilus Influenzae Type B Vaccine Market by Manufacturers
3.1 Global Haemophilus Influenzae Type B Vaccine Revenue by Manufacturers (2020-2025)
3.2 Global Haemophilus Influenzae Type B Vaccine Sales by Manufacturers (2020-2025)
3.3 Global Haemophilus Influenzae Type B Vaccine Average Sales Price by Manufacturers (2020-2025)
3.4 Global Haemophilus Influenzae Type B Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Haemophilus Influenzae Type B Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Haemophilus Influenzae Type B Vaccine Manufacturers, Product Type & Application
3.7 Global Haemophilus Influenzae Type B Vaccine Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Haemophilus Influenzae Type B Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Haemophilus Influenzae Type B Vaccine Players Market Share by Revenue in 2024
3.8.3 2024 Haemophilus Influenzae Type B Vaccine Tier 1, Tier 2, and Tier 3
4 Haemophilus Influenzae Type B Vaccine Market by Type
4.1 Haemophilus Influenzae Type B Vaccine Type Introduction
4.1.1 Liquid Combination HIB
4.1.2 Liquid Monovalent HIB
4.1.3 Lyophilized Combination HIB
4.1.4 Lyophilized Monovalent HIB
4.2 Global Haemophilus Influenzae Type B Vaccine Sales by Type
4.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Haemophilus Influenzae Type B Vaccine Sales by Type (2020-2031)
4.2.3 Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Type (2020-2031)
4.3 Global Haemophilus Influenzae Type B Vaccine Revenue by Type
4.3.1 Global Haemophilus Influenzae Type B Vaccine Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Type (2020-2031)
4.3.3 Global Haemophilus Influenzae Type B Vaccine Revenue Market Share by Type (2020-2031)
5 Haemophilus Influenzae Type B Vaccine Market by Application
5.1 Haemophilus Influenzae Type B Vaccine Application Introduction
5.1.1 Pharmaceutical and Biotechnology Companies
5.1.2 Hospital
5.1.3 Research Institutions
5.1.4 Academic Institutions
5.1.5 Other
5.2 Global Haemophilus Influenzae Type B Vaccine Sales by Application
5.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Haemophilus Influenzae Type B Vaccine Sales by Application (2020-2031)
5.2.3 Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Application (2020-2031)
5.3 Global Haemophilus Influenzae Type B Vaccine Revenue by Application
5.3.1 Global Haemophilus Influenzae Type B Vaccine Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Application (2020-2031)
5.3.3 Global Haemophilus Influenzae Type B Vaccine Revenue Market Share by Application (2020-2031)
6 Global Haemophilus Influenzae Type B Vaccine Sales by Region
6.1 Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Haemophilus Influenzae Type B Vaccine Sales by Region (2020-2031)
6.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Region (2020-2025)
6.2.2 Global Haemophilus Influenzae Type B Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Haemophilus Influenzae Type B Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Haemophilus Influenzae Type B Vaccine Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Haemophilus Influenzae Type B Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Haemophilus Influenzae Type B Vaccine Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Haemophilus Influenzae Type B Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Haemophilus Influenzae Type B Vaccine Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Haemophilus Influenzae Type B Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Haemophilus Influenzae Type B Vaccine Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Haemophilus Influenzae Type B Vaccine Revenue by Region
7.1 Global Haemophilus Influenzae Type B Vaccine Revenue by Region
7.1.1 Global Haemophilus Influenzae Type B Vaccine Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Region (2020-2025)
7.1.3 Global Haemophilus Influenzae Type B Vaccine Revenue by Region (2026-2031)
7.1.4 Global Haemophilus Influenzae Type B Vaccine Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Haemophilus Influenzae Type B Vaccine Revenue (2020-2031)
7.2.2 North America Haemophilus Influenzae Type B Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Haemophilus Influenzae Type B Vaccine Revenue (2020-2031)
7.3.2 Europe Haemophilus Influenzae Type B Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue (2020-2031)
7.4.2 Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Takeda Pharmaceuticals Company
8.1.1 Takeda Pharmaceuticals Company Comapny Information
8.1.2 Takeda Pharmaceuticals Company Business Overview
8.1.3 Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Product Portfolio
8.1.5 Takeda Pharmaceuticals Company Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Haemophilus Influenzae Type B Vaccine Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Haemophilus Influenzae Type B Vaccine Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Merck
8.4.1 Merck Comapny Information
8.4.2 Merck Business Overview
8.4.3 Merck Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Merck Haemophilus Influenzae Type B Vaccine Product Portfolio
8.4.5 Merck Recent Developments
8.5 Lanzhou Institute of Biologica
8.5.1 Lanzhou Institute of Biologica Comapny Information
8.5.2 Lanzhou Institute of Biologica Business Overview
8.5.3 Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Product Portfolio
8.5.5 Lanzhou Institute of Biologica Recent Developments
8.6 GlaxoSmithKline
8.6.1 GlaxoSmithKline Comapny Information
8.6.2 GlaxoSmithKline Business Overview
8.6.3 GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Product Portfolio
8.6.5 GlaxoSmithKline Recent Developments
8.7 Walvax Biotechnology
8.7.1 Walvax Biotechnology Comapny Information
8.7.2 Walvax Biotechnology Business Overview
8.7.3 Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Product Portfolio
8.7.5 Walvax Biotechnology Recent Developments
8.8 Immunize BC
8.8.1 Immunize BC Comapny Information
8.8.2 Immunize BC Business Overview
8.8.3 Immunize BC Haemophilus Influenzae Type B Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Immunize BC Haemophilus Influenzae Type B Vaccine Product Portfolio
8.8.5 Immunize BC Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Haemophilus Influenzae Type B Vaccine Value Chain Analysis
9.1.1 Haemophilus Influenzae Type B Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Haemophilus Influenzae Type B Vaccine Production Mode & Process
9.2 Haemophilus Influenzae Type B Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Haemophilus Influenzae Type B Vaccine Distributors
9.2.3 Haemophilus Influenzae Type B Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.